



Henri A. Termeer

Henri A. Termeer was appointed president of Genzyme Corporation in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. Under his leadership, Genzyme has grown from a modest entrepreneurial venture to one of the world's leading biotechnology companies.

Mr. Termeer is recognized as a pioneer in developing and delivering treatments to patients with rare genetic diseases around the world. This work has provided the foundation for Genzyme's success, and today the company is diversified across medical areas including genetic diseases, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. He serves on the board of directors of the Pharmaceutical Research and Manufacturers of America. He is a director of Massachusetts General Hospital, a board member of Partners HealthCare and a member of the board of fellows of Harvard Medical School.

Mr. Termeer is chairman of the Federal Reserve Bank of Boston's board of directors and a board member of Abiomed Inc. In 2008, he was appointed to Massachusetts Governor Deval Patrick's Council of Economic Advisors, and he is a co-chair of the Leadership Council of the Mass. Life Sciences Collaborative. Mr. Termeer is also chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding.

Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.



Jason A. Amello

Senior Vice President, Finance; Corporate Controller; Chief Accounting Officer

Jason Amello joined Genzyme in 2000. He oversees and directs all aspects of the company's accounting operations, including the selection and implementation of significant accounting policies; valuation of assets; internal controls, processes and reporting; and external financial reporting to the Securities and Exchange Commission. He is also responsible for providing financial advisory and support services for strategic transactions and assists the company's business units in mergers and acquisitions, product acquisition and corporate partnering transactions.

Mr. Amello was vice president of strategic financial services from 2004 to 2008. From 2000 to 2004, he served as the assistant corporate controller. Prior to joining Genzyme, he worked as a certified public accountant in the business advisory and assurance practice of Deloitte & Touche LLP. Mr. Amello has a B.S. from Boston College.



John P. Butler

Senior Vice President; President, Personalized Genetic Health

John Butler joined Genzyme in 1997 as product manager for Renagel. He has led the company's renal, endocrine, and cardiovascular businesses, managing Genzyme's approved products as well as the development of Genzyme's cardiometabolic and renal portfolio. In 2010, Mr. Butler was appointed president of Genzyme's Personalized Genetic Health business unit. He will oversee Genzyme's personalized genetic health portfolio of products, including lysosomal storage disorder treatments and cardiovascular products.

Mr. Butler has also served as vice president of strategic planning, vice president of Renagel Europe, and senior vice president and general manager of the renal business unit. Prior to joining Genzyme, he worked in sales and marketing at Amgen Inc.

Mr. Butler has an M.B.A. from Baruch College and a B.A. from Manhattan College.



Scott Canute

Executive Vice President; President, Global Manufacturing and Corporate Operations
Scott Canute joined Genzyme in 2010. He oversees the production of Genzyme's diverse range of products manufactured at 17 sites around the world.

Mr. Canute is the former manufacturing head of Eli Lilly & Company, where he directed all manufacturing and supply chain activities for the company's operations. He has experience with a variety of technologies, including biologics, small and large molecules, and devices. During his 25-year career, he has resolved significant challenges, including FDA warning letters and 483 post-inspection letters. He has also managed multiple product launches and the development of new manufacturing sites.

Mr. Canute holds a degree in chemical engineering from the University of Michigan and an M.B.A. from Harvard Business School.



Zoltan Csimma

Senior Vice President; Chief Human Resources Officer
Zoltan Csimma joined Genzyme in 2000. He manages Genzyme's corporate human resources organization, and is also responsible for developing global human resources strategies and programs. Prior to joining Genzyme, Mr. Csimma was vice president of human resources at Wyeth Ayerst Research, and vice president of human resources and operations at Genetics Institute Inc. Mr. Csimma has also worked in human resources roles for Convergent Inc., Spectra Physics Inc., and General Electric Co. He received his B.A. from the California State University at San Jose.



Thomas J. DesRosier, Esquire

Senior Vice President; General Counsel; Chief Legal Officer
Thomas DesRosier joined Genzyme in 1999. He is responsible for the management of the company's legal affairs worldwide, including supervision of more than 50 internal legal professionals. Before he joined Genzyme, Mr. DesRosier was assistant general counsel for patents at American Home Products Corp., where he directed intellectual property efforts for the company's pharmaceutical products. Mr. DesRosier has also served as vice president and chief patent counsel for Genetics Institute Inc. and held several intellectual property positions at E.I. DuPont de Nemours and Company and New England Nuclear Corp. He earned a J.D. from Wake Forest University School of Law and a B.A. from the University of Vermont.



Richard Douglas, Ph.D.

Senior Vice President, Corporate Development
Richard Douglas joined Genzyme in 1989. He is responsible for evaluating and acquiring new products, programs and companies for the corporation. Dr. Douglas helps develop growth plans for Genzyme and each of its business units and subsidiaries. Prior to joining Genzyme, Dr. Douglas was director of new product development at Integrated Genetics. He has also served as the company's manager of protein chemistry research. Dr. Douglas had a post doctoral fellowship at the California Institute of Technology and received his Ph.D. in biochemistry from the University of California, Berkeley. He also has a B.S. from the University of Michigan.



Mark J. Enyedy

Senior Vice President; President, Genetics, Transplant, Oncology & Multiple Sclerosis

Mark Enyedy joined Genzyme in 1996. He oversees the company's growing Transplant & Oncology and Genetics business units as well as the program to develop and commercialize alemtuzumab for multiple sclerosis. He is also responsible for managing the units' mergers and acquisitions, product acquisition and corporate partnering transactions.

Before joining Genzyme, Mr. Enyedy practiced law at Palmer & Dodge, a Boston law firm, where he represented a number of clients in the biopharmaceutical industry in acquisition, partnering and financing transactions.

Mr. Enyedy received a J.D. from Harvard Law School and a B.S. from Northeastern University.



David D. Fleming

Group Senior Vice President

David Fleming joined Genzyme in 1984. He oversees worldwide operations and distribution for the Genzyme Diagnostics business unit. He is also responsible for corporate initiatives including e-business strategy, payment and health care delivery policy and Medicare reform. Prior to Genzyme, Mr. Fleming held general management, sales and marketing positions during 11 years at Baxter International with an emphasis on diagnostics, therapeutics and international business development. He began his career as a high school teacher. Mr. Fleming has an M.B.A. from Pepperdine University and a B.A. from the College of Wooster.



James A. Geraghty

Senior Vice President

James Geraghty joined Genzyme in 1992. He is responsible for corporate development, product acquisition and partnering transactions. He led Genzyme's recent licensing deal with Isis Pharmaceuticals and the acquisition of SangStat Medical Corporation in 2003. He oversaw the commercialization of Cholestagel in Europe and has served as president of Genzyme Europe.

Prior to joining Genzyme, Mr. Geraghty was vice president of marketing and strategic planning for Baxter/Caremark International. He has also worked as a consultant on international health care strategy at Bain and Company.

Mr. Geraghty has a J.D. from Yale Law School, an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.



Carlo Incerti, M.D.

Senior Vice President Global Market Access

Dr. Carlo Incerti joined Genzyme in 1992. He is responsible for Global Market Access, which includes Global Regulatory Affairs and Compliance, Corporate Quality Systems, Global Strategic Pricing & Health Outcomes, Global Patient Safety and Risk Management and Global Policy Programs. He previously served in medical, regulatory and research and development roles in Europe. During his tenure, Dr. Incerti successfully led the European Clinical and Regulatory Affairs group in gaining Marketing Authorization Approvals in Europe for all of Genzyme's products.

Dr. Incerti is a board-certified endocrinologist who started his career in the medical profession as a staff member and then as associate professor at the Department of Endocrinology of Modena University Hospital in Italy. He received his M.D. from the University of Modena.



Alison Lawton

Senior Vice President; General Manager, Biosurgery

Alison Lawton joined Genzyme in 1991 as an international regulatory affairs specialist. As head of Genzyme Biosurgery, Ms. Lawton is responsible for our global orthopedics, biosurgical specialty (BSS) and cell therapy and regenerative medicine (CT&RM) businesses. The orthopedic business includes the Synvisc and Jonexa franchises; the BSS business consists of Septrafilm; and the CT&RM products include the autologous cell therapies Carticel, MACI and Epicel. Prior to this role, Ms. Lawton oversaw Global Market Access at Genzyme, which included Regulatory Affairs, Global Health Outcomes and Strategic Pricing, Global Public Policy and Global Product Safety & Risk Management.

Before coming to Genzyme, Ms. Lawton worked for seven years at Parke-Davis in the U.K. She has a B.S. from the University of London.



Roger W. Louis, Esquire

Senior Vice President, Healthcare and Regulatory Counsel, and Chief Compliance Officer

Roger Louis joined Genzyme in 1997. He is responsible for the company's corporate compliance program and is the managing counsel for compliance and health. Prior to joining Genzyme, Mr. Louis was corporate, strategic and finance chief counsel for Blue Cross and Blue Shield of Massachusetts. He has also worked as an associate in the corporate and securities department at Hale and Dorr. Mr. Louis has a J.D. from the University of Chicago School of Law and a B.A. from Tufts University.



Mary McGrane

Vice President; Senior Vice President, Government Relations

Mary McGrane joined Genzyme in 1999. She focuses on issues and legislation of specific concern to Genzyme, including Medicare, Medicaid, orphan drugs and the Food and Drug Administration. Prior to joining Genzyme, Ms. McGrane headed the Government Relations Department at Rhone-Poulenc Rorer Pharmaceuticals Inc. Before taking that position, she had spent 12 years on Capitol Hill. During eight of those years she was a staff member of the House Committee on Energy and Commerce, serving at various times as either Minority or Majority Counsel. Ms. McGrane has a J.D. from Catholic University School of Law and a M.A. from Drew University.



John McPherson, Ph.D.

Senior Vice President, Biologics Research and Development

John McPherson joined Genzyme in 1989. He directs scientific research programs focused on development and commercialization of cell and protein-based therapeutic products. Before he came to Genzyme, Dr. McPherson was director of protein chemistry at Integrated Genetics. He also worked for Collagen Corporation, and was research project leader for their soft tissue wound healing program. Dr. McPherson had a post-doctoral fellowship at the University of Washington School of Medicine. He has a Ph.D. in biochemistry from the University of California, Davis. He also has a M.A. from the University of California, Davis and a B.A. from the University of California, Berkeley.



David Meeker, M.D.

Chief Operating Officer

Dr. Meeker is responsible for Genzyme's commercial organization, overseeing the company's business units, country management organization, and global market access functions. He works to maximize the potential of the company's broad portfolio of products, most of which are in their growth phases.

Prior to joining Genzyme, Dr. Meeker was the director of the pulmonary critical care fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker attended Dartmouth College and received his M.D. from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.



C. Ann Merrifield

Senior Vice President, Business Excellence Initiative

Ann Merrifield joined Genzyme in 1992. She serves as Senior Vice President of the Genzyme Business Excellence Initiative (BEI). BEI is a strategic evaluation capability supporting the corporation in preparing Genzyme's organization for the next phase of innovation and sustainable growth. Ms. Merrifield has also served as president of Genzyme Genetics and president of Genzyme Biosurgery. Prior to joining Genzyme in 1992, she was a partner at Bain and Company and an investment analyst for Aetna Life and Casualty. Ms. Merrifield has an M.B.A. from the Tuck School at Dartmouth College and a B.A. and M.Ed. from the University of Maine.



Richard A. Moscicki, M.D.

Senior Vice President, Clinical Development and Medical Affairs; Chief Medical Officer

Richard Moscicki joined Genzyme in 1992. He has worldwide responsibility for all aspects of clinical research, medical decisions, pharmacovigilance and regulatory. Before joining Genzyme, Dr. Moscicki was chief of immunology and allergy at Massachusetts Eye and Ear Infirmary, where he continues to work as a consultant. He also served as a staff member of Massachusetts General Hospital and has been a faculty member at Harvard Medical School since 1979. Dr. Moscicki earned his B.S. and M.D. from Northwestern University.



Donald E. Pogorzelski

Vice President; President, Diagnostic Products

Donald Pogorzelski joined Genzyme in 1988. He is responsible for managing all aspects of the worldwide diagnostics business unit, including Genzyme Virotech in Russelsheim, Germany, the rapid test products in San Diego, California, and facilities in Kent, United Kingdom, and Cambridge, Massachusetts. Mr. Pogorzelski's initial responsibility at Genzyme was sales and marketing for raw materials for the domestic clinical chemistry market. Prior to joining Genzyme, he held positions in human resources, finance, and sales and marketing at Abbott Laboratories. Mr. Pogorzelski has an M.B.A. from the University of Chicago and a B.S. from Loyola University of Chicago.



Alan E. Smith, Ph.D.

Senior Vice President, Research; Chief Scientific Officer

Alan Smith joined Genzyme in 1989. He has overall responsibility for the company's science. Before Integrated Genetics was acquired by Genzyme in 1989, Dr. Smith was that company's vice president and scientific director. Prior to joining Integrated Genetics, he was head of the Biochemistry Division of the National Institute for Medical Research, Mill Hill, in London. Dr. Smith has also served as a member of the scientific staff at London's Imperial Cancer Research Fund. Dr. Smith has a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England and a B.A. from Christ's College, Cambridge, England.



Sandford D. Smith

Executive Vice President; President, International Group

Sandford Smith joined Genzyme in 1996. He is responsible for all of Genzyme's commercial activities for the lysosomal storage disorder, renal, transplant and biosurgery products outside of the United States. Mr. Smith served as vice president and general manager of Genzyme International and president of Genzyme Specialty Therapeutics before being named to his current position in 1998. Prior to joining Genzyme, Mr. Smith was president and chief executive officer at Repligen Corporation. He has also served as vice president of business development and strategic planning for Bristol-Myers Squibb Company. Mr. Smith has a B.A. from the University of Denver.



Gail F. Sullivan

Treasurer

Gail Sullivan joined Genzyme in 2007. She is responsible for Genzyme's global treasury operations, including corporate financing, cash management, risk management, and investment management.

Prior to joining Genzyme, Ms. Sullivan was vice president and treasurer of The Gillette Company. She has also held various managerial and financial positions at Gillette and at Digital Equipment Corporation.

Ms. Sullivan has an M.B.A. from the Tuck School of Business at Dartmouth and a B.A. from Dartmouth College.



Peter Wirth, Esquire

Executive Vice President, Legal and Corporate Development; Secretary

Peter Wirth joined Genzyme in 1996 after having served as the company's outside general counsel since 1982. He has senior management responsibility for the corporate development and legal departments. Prior to joining Genzyme, he was a partner at Palmer and Dodge, a Boston law firm, where he was head of the firm's technology group. Mr. Wirth has a J.D. from Harvard Law School and a B.A. from the University of Wisconsin.



Michael S. Wyzga

Executive Vice President, Finance; Chief Financial Officer

Michael Wyzga joined Genzyme in 1998, and is responsible for global financial reporting. Prior to joining Genzyme, Mr. Wyzga was chief financial officer of Sovereign Hill Software Inc. He also served as vice president of finance and chief financial officer of CacheLink Corporation, a client/service software company. Mr. Wyzga has also held management positions at both Lotus Development Corporation and Digital Equipment Corporation. Mr. Wyzga has an M.B.A. from Providence College and a B.S. from Suffolk University.